Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-13T06:59:23.082Z Has data issue: false hasContentIssue false
  • English
  • Français

Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression

Published online by Cambridge University Press:  06 August 2012

Christopher T. Lum  and
Stephen M. Stahl
Christopher T. Lum*
Affiliation:
Arbor Scientia, Carlsbad, California, USA
Stephen M. Stahl
Affiliation:
Department of Psychiatry, University of California–San Diego, San Diego, California, USA
*
*Address for correspondence: Christopher T. Lum, Arbor Scientia, 1930 Palomar Point Way, Ste. 100, Carlsbad, CA 92108, USA. (Email [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Treatment-resistant depression (TRD) may be implicated in 33–57% of depression cases. The currently available effective treatments include electroconvulsive therapy (ECT) or augmentation of serotonin selective reuptake inhibitors (SSRIs) with antipsychotics. ECT and antipsychotics are both associated with safety and tolerability concerns. Depression is hypothesized to result from a dysregulation of monoamine neurotransmitters, although the source of the dysregulation has been unclear. However, recent studies have revealed that an enzyme that degrades the neurotransmitters, known as monamine oxidase-A (MAO-A), may be overactive in patients with depression. Thus, treatments for depression that modulate MAO-A could act upstream relative to current antidepressant treatments. Monoamine oxidase inhibitors (MAOIs) can be highly effective therapeutic agents for depression and some anxiety disorders. Some evidence suggests that MAOIs may act by reversing excessive neurotransmitter depletion within the neuron and the synapse. MAOIs tend to be underutilized in clinical practice, due in part to misinformation and mythology about their dietary and drug interactions. The new class of reversible monoamine oxidase inhibitors (RIMAs) has shown efficacy in depression, with safety and tolerability comparable to SSRIs. This article discusses recent progress in RIMAs toward the treatment of TRD. Dietary and drug interactions of MAOIs will be covered, as well as guidelines for integrating these agents into clinical practice.

Keywords

Treatment resistant depressionreversible monoamine oxidase inhibitorserotonin syndromehypertensiondietary interactiondrug interaction
Type
Opinion
Information
CNS Spectrums , Volume 17 , Issue 3 , September 2012 , pp. 107 - 120
Copyright
Copyright © Cambridge University Press 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Kessler, RC, Berglund, P, Demler, O, et al. . The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23): 3095–3105.CrossRefGoogle ScholarPubMed
2.Greenberg, PE, Kessler, RC, Birnbaum, HG, et al. . The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003; 64(12): 1465–1475.CrossRefGoogle ScholarPubMed
3.Ioannidis, JP. Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? Philos Ethics Humanit Med. 2008; 3: 14.CrossRefGoogle ScholarPubMed
4.Golden, SH, Williams, JE, Ford, DE, et al. . Depressive symptoms and the risk of type 2 diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care. 2004; 27(2): 429–435.CrossRefGoogle ScholarPubMed
5.Jonas, BS, Franks, P, Ingram, DD. Are symptoms of anxiety and depression risk factors for hypertension? Longitudinal evidence from the National Health and Nutrition Examination Survey I Epidemiologic Follow-Up Study. Arch Fam Med. 1997; 6(1): 43–49.CrossRefGoogle ScholarPubMed
6.Larson, SL, Owens, PL, Ford, D, Eaton, W. Depressive disorder, dysthymia, and risk of stroke: thirteen-year follow-up from the Baltimore epidemiologic catchment area study. Stroke. 2001; 32(9): 1979–1983.CrossRefGoogle ScholarPubMed
7.Nelson, JC. The STAR*D study: a four-course meal that leaves us wanting more. Am J Psychiatry. 2006; 163(11): 1864–1866.CrossRefGoogle ScholarPubMed
8.Rush, AJ, Trivedi, MH, Wisniewski, SR, et al. . Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006; 163(11): 1905–1917.CrossRefGoogle ScholarPubMed
9.Crown, WH, Finkelstein, S, Berndt, ER, et al. . The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002; 63(11): 963–971.CrossRefGoogle ScholarPubMed
10.Shelton, RC, Osuntokun, O, Heinloth, AN, Corya, SA. Therapeutic options for treatment-resistant depression. CNS Drugs. 2010; 24(2): 131–161.CrossRefGoogle ScholarPubMed
11.Stahl, SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. fully rev. expanded ed. Cambridge, UK: Cambridge University Press; 2008.Google Scholar
12.Meyer, JH, Ginovart, N, Boovariwala, A, et al. . Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 2006; 63(11): 1209–1216.CrossRefGoogle Scholar
13.Meyer, JH, Wilson, AA, Sagrati, S, et al. . Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch Gen Psychiatry. 2009; 66(12): 1304–1312.CrossRefGoogle ScholarPubMed
14.Johnson, S, Stockmeier, CA, Meyer, JH, et al. . The reduction of r1, a novel repressor protein for monoamine oxidase a, in major depressive disorder. Neuropsychopharmacology. 2011; 36(10): 2139–2148.CrossRefGoogle ScholarPubMed
15.Atchley, DW. Reevaluation of tranylcypromine sulfate. JAMA. 1964; 189: 763–764.Google ScholarPubMed
16.Grady, M, Stahl, SM. Practical guide for prescribing MAOIs: debunking myths and removing barriers. CNS Spectr. 2012; 17: 2–10.CrossRefGoogle ScholarPubMed
17.Billett, EE. Monoamine oxidase (MAO) in human peripheral tissues. Neurotoxicology. 2004; 25(1–2): 139–148.CrossRefGoogle ScholarPubMed
18.Lotufo-Neto, F, Trivedi, M, Thase, ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999; 20(3): 226–247.CrossRefGoogle ScholarPubMed
19.Bieck, PR, Antonin, KH. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm Suppl. 1989; 28: 21–31.Google ScholarPubMed
20.Wimbiscus, M, Kostenko, O, Malone, D. MAO inhibitors: risks, benefits, and lore. Cleve Clin J Med. 2010; 77(12): 859–882.CrossRefGoogle ScholarPubMed
21.Stahl, SM, Felker, A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008; 13(10): 855–870.CrossRefGoogle Scholar
22.Elis, J, Laurence, DR, Mattie, H, Prichard, BN. Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure. Br Med J. 1967; 2(5544): 75–78.CrossRefGoogle ScholarPubMed
23.Boakes, AJ, Laurence, DR, Teoh, PC, et al. . Interactions between sympathomimetic amines and antidepressant agents in man. Br Med J. 1973; 1(5849): 311–315.CrossRefGoogle ScholarPubMed
24.Horwitz, D, Goldberg, LI, Sjoerdsma, A. Increased blood pressure responses to dopamine and norepinephrine produced by monoamine oxidase inhibitors in man. J Lab Clin Med. 1960; 56: 747–753.Google ScholarPubMed
25.Yagiela, JA, Duffin, SR, Hunt, LM. Drug interactions and vasoconstrictors used in local anesthetic solutions. Oral Surg Oral Med Oral Pathol. 1985; 59(6): 565–571.CrossRefGoogle ScholarPubMed
26.Wells, DG, Bjorksten, AR. Monoamine oxidase inhibitors revisited. Can J Anaesth. 1989; 36(1): 64–74.CrossRefGoogle Scholar
27.Sun-Edelstein, C, Tepper, SJ, Shapiro, RE. Drug-induced serotonin syndrome: a review. Expert Opin Drug Saf. 2008; 7(5): 587–596.CrossRefGoogle ScholarPubMed
28.Hilton, SE, Maradit, H, Moller, HJ. Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Eur Arch Psychiatry Clin Neurosci. 1997; 247(3): 113–119.CrossRefGoogle ScholarPubMed
29.Stahl, SM. Stahl's Essential Psychopharmacology: The Prescriber's Guide. Antidepressants. 4th ed. Cambridge, UK: Cambridge University Press; 2011.CrossRefGoogle Scholar
30.Raymond, CB, Morgan, SG, Caetano, PA. Antidepressant utilization in British Columbia from 1996 to 2004: increasing prevalence but not incidence. Psychiatr Serv. 2007; 58(1): 79–84.CrossRefGoogle Scholar
31.Karkare, SU, Bhattacharjee, S, Kamble, P, Aparasu, R. Prevalence and predictors of antidepressant prescribing in nursing home residents in the United States. Am J Geriatr Pharmacother. 2011; 9(2): 109–119.CrossRefGoogle ScholarPubMed
32.Shulman, KI, Fischer, HD, Herrmann, N, et al. . Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults. J Clin Psychiatry. 2009; 70(12): 1681–1686.CrossRefGoogle ScholarPubMed
33.Coupland, C, Dhiman, P, Barton, G, et al. . A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technol Assess. 2011; 15(28): 1–202.CrossRefGoogle ScholarPubMed
34.Fowler, JS, Logan, J, Azzaro, AJ, et al. . Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010; 35(3): 623–631.CrossRefGoogle ScholarPubMed
35.VanDenBerg, CM, Blob, LF, Kemper, EM, Azzaro, AJ. Tyramine pharmacokinetics and reduced bioavailability with food. J Clin Pharmacol. 2003; 43(6): 604–609.CrossRefGoogle Scholar
36. Burch D, Asgharnejad M, Gerson W. Lack of tyramine pressor response effect with oral CX157, a reversible MAOI. Paper presented at: American College of Neuropsychopharmacology, 50th annual meeting; December 4–8, 2011; Waikoloa Beach, HI.CrossRefGoogle Scholar
37.Azzaro, AJ, Vandenberg, CM, Blob, LF, et al. . Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects. J Clin Pharmacol. 2006; 46(8): 933–944.CrossRefGoogle Scholar